.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fuji
Deloitte
Express Scripts
Cerilliant
Harvard Business School
UBS
US Department of Justice
Teva
Moodys

Generated: December 12, 2017

DrugPatentWatch Database Preview

Eli Lilly And Co Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?

ELI LILLY AND CO has six approved drugs.

There are nineteen US patents protecting ELI LILLY AND CO drugs.

There are two hundred and sixty-seven patent family members on ELI LILLY AND CO drugs in fifty-four countries and fifty-nine supplementary protection certificates in twelve countries.

Summary for Eli Lilly And Co

International Patents:267
US Patents:19
Tradenames:7
Ingredients:6
NDAs:6
Drug Master File Entries: 37
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-003Jun 15, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Eli Lilly And CoHUMALOG KWIKPENinsulin lispro recombinantSOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoVERZENIOabemaciclibTABLET;ORAL208716-004Sep 28, 2017RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-006Dec 23, 1992AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoVERZENIOabemaciclibTABLET;ORAL208716-004Sep 28, 2017RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Eli Lilly And CoSARAFEMfluoxetine hydrochlorideCAPSULE;ORAL018936-008Jul 6, 2000DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eli Lilly And CoEFFIENTprasugrel hydrochlorideTABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And CoSARAFEMfluoxetine hydrochlorideCAPSULE;ORAL018936-008Jul 6, 2000► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-003Jun 15, 1999► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-003Jun 15, 1999► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-004Jun 15, 1999► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And CoPROZACfluoxetine hydrochlorideCAPSULE;ORAL018936-006Dec 23, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ELI LILLY AND CO drugs

Drugname Dosage Strength Tradename Submissiondate
prasugrel hydrochlorideTablets5 mg and 10 mgEFFIENT7/10/2013
testosteroneTopical Solution30 mg/1.5 mLAXIRON1/29/2013

Premature patent expirations for ELI LILLY AND CO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,998,138Topical delivery of anti-alopecia agents► Subscribe
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation► Subscribe
8,177,449Spreading implement► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,427,275Medication dispensing apparatus with triple screw threads for mechanical advantage► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
6,964,777 Transdermal delivery of antianxiety agents► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eli Lilly And Co Drugs

Country Document Number Estimated Expiration
Hong Kong1159630► Subscribe
Portugal901368► Subscribe
Australia734781► Subscribe
Israel213350► Subscribe
South Africa9804697► Subscribe
China1154496► Subscribe
BrazilPI0611134► Subscribe
Slovenia2379528► Subscribe
Portugal1674068► Subscribe
China1041730► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90067-4Sweden► SubscribePRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
2009 00024Denmark► Subscribe
2107069/02Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
2013000062Germany► SubscribePRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
60026Netherlands► SubscribePRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
13/34Ireland► SubscribePRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
C/GB09/032United Kingdom► SubscribePRODUCT NAME: PRASUGREL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/08/503/001 20090225; UK EU/1/08/503/002 20090225; UK EU/1/08/503/003 20090225; UK EU/1/08/503/004 20090225
/2004Austria► SubscribePRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Cipla
Johnson and Johnson
Baxter
Moodys
Express Scripts
Farmers Insurance
Chubb
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot